logo-loader

HemoGenyx CEO 'overwhelmed' by speed of progress at the company

Published: 16:15 26 Jun 2018 BST

Dr Vladislav Sandler, chief executive of HemoGenyx Pharmaceuticals PLC (LON:HEMO), caught up with Proactive's Andrew Scott while in London to meet with investors.

It's been nearly nine months now since the company first listed in London and in that time they've inked four collaborations with leading universities and pharmaceutical companies.

Dr Sandler says all is on track and work is “progressing successfully” towards  the goal of submitting an investigational new drug application to the US Food and Drug Administration for their CDX antibodies product.

Hemogenyx Pharmaceuticals discusses successful £3.5M capital raise as it...

Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) Dr Vladislav Sandler joins Proactive's Stephen Gunnion after the pre-clinical stage biopharmaceutical group raised £3.5 million, which will be utilized to progress its lead product candidate, Chimeric Antigen Receptor T-cells (HEMO-CAR-T), into...

6 days, 23 hours ago